Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michael Amoroso
AddedFeb 19, 2024
UpdatedMay 31, 2026
Michael Amoroso

Michael Amoroso

Board Member, Abeona Therapeutics

CrunchbaseLinkedInThe Org

Michael Amoroso's Career

Abeona Therapeutics
Abeona Therapeutics

New York City, NY, US

Board Member· Board
Precision BioSciences
Precision BioSciences

Durham, NC, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michael Amoroso's Career

Abeona Therapeutics
Abeona Therapeutics
Public$354.7M951989New York City, NY, US
Board Member· Board

Leadership at Abeona Therapeutics

Mark AhnMark AhnBoard Member
Haiyan FuHaiyan FuCo-Founder
Vishwas SeshadriVishwas SeshadriCEO
Leila AllandLeila AllandBoard Member
Douglas McCartyDouglas McCartyCo-Founder

Similar to Abeona Therapeutics

Apertura Gene TherapyApertura Gene TherapyNew York City, NY, USGene Therapyest. 2021Apertura Gene TherapyNew York City, NY, US · est. 2021

Apertura Gene Therapy: A biotech firm pioneering gene therapy for debilitating diseases.

Series A · $67M29
AgtcAgtcAlachua, FL, USGene Therapyest. 1999AgtcAlachua, FL, US · est. 1999

AGTC: A biotech firm conducting clinical trials for AAV-based gene therapies for rare diseases.

Public · $195.1M350
Atsena TherapeuticsAtsena TherapeuticsDurham, NC, USGene Therapyest. 2019Atsena TherapeuticsDurham, NC, US · est. 2019

Atsena Therapeutics: A clinical-stage gene therapy company targeting inherited blindness.

Series B · $87.6M55
Akebia TherapeuticsAkebia TherapeuticsCambridge, MA, USTherapeuticsest. 2007Akebia TherapeuticsCambridge, MA, US · est. 2007

Akebia Therapeutics, a US-based firm, develops and distributes novel HIF-based therapeutics for kidney diseases.

Public · $442.5M205
Precision BioSciences
Precision BioSciences
Public$225.2M1982006Durham, NC, US
CEO· C-Suite · Management

Leadership at Precision BioSciences

Derek JantzDerek JantzBoard Member
Melinda BrownMelinda BrownBoard Member
Ben AuspitzBen AuspitzBoard Member
Geno GermanoGeno GermanoBoard Member
Matthew KaneMatthew KaneBoard Member
Shalini SharpShalini SharpBoard Member

People Similar to Michael Amoroso

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoPhilip ArlenPhilip ArlenCEO · Precision BiologicsAryeh BattAryeh BattCo-Founder · Precise BioJeff SmithJeff SmithFounder · Precision BioSciencesFayaz KhaziFayaz KhaziFounder · TraitologySam WadsworthSam WadsworthBoard Member · Precision BioSciences